Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (breast myoepithelial cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: barusiban, atosiban, retosiban +5 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 1,382 | 0.82 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3510
Sealed predictions
- OXTR in dopamine neurons, braak+0.24 (p 0.533) → -0.42 (p 0.265)receipt 3518
Swarm cases
receipt 3518: OXTR in dopamine neurons, braak
- power
- full sample +0.05 (p 0.840, n 18), 95% CI -0.43 to +0.51. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.956, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.11 (p 0.658, n 18). could be the mix.
- skeptic
- leave-one-out range -0.10 to +0.18, sign flips 4; without severely affected donors +0.05 (p 0.840, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for OXTR in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts